Lexicon Pharmaceuticals (LXRX) Operating Leases (2022 - 2024)

Lexicon Pharmaceuticals (LXRX) has 3 years of Operating Leases data on file, last reported at $6.4 million in Q1 2024.

• Operating Leases for Q1 2024 came in at $6.4 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2024 was $6.4 million (changed N/A YoY), and the FY2023 annual result was $5.3 million, down 2.5% from the prior year.
• Operating Leases advanced to $6.4 million in Q1 2024 per LXRX's latest filing, from $5.3 million in the prior quarter.
• Over five years, Operating Leases peaked at $6.4 million in Q1 2024 and troughed at $5.3 million in Q4 2023.
• A 3-year average of $5.6 million and a median of $5.4 million in 2022 frame the typical range for Operating Leases.
• On a YoY basis, Operating Leases climbed as much as 2.5% in 2023 and fell as far as 2.5% in 2023.
• A 3-year view of Operating Leases shows it stood at $5.4 million in 2022, then fell by 2.5% to $5.3 million in 2023, then increased by 20.99% to $6.4 million in 2024.
• Business Quant data shows LXRX's Operating Leases at $6.4 million in Q1 2024, $5.3 million in Q4 2023, and $5.4 million in Q3 2023.